FIELD OF THE INVENTION: The invention relates to Topical pharmaceutic• I agents preparation and useful in the treatment of inflammatory-rela,tbd conditions. More specifically, this invention relates to Topical pharmaceutical formulations that more rapidly reduce condition symptoms and 5 address the underlying cause of the condition would be a significant advancement in the art. BACKGROUND OF THE INVENTION: The present invention provides the formulation development of chrysabolol started with ointment imd cream formulations for phase I ;md phase 2 clinical studies. It has been 10 determined that ointment-formulations are desir<~ble for the treatment of inflammatory skin diseases, in part due to the beneficial softening properties of the ointment. The initial formulation consisted of a partial suspension of chrysabolol, but chemical and physical stability issues were problematic and required a different approach. ··l . The present invention relates to a pharmaceutical composition containing a combination of 15 chrysabolol, chrysabolol and other active agents and methods of using the same. Summary of the invention: The present invention also contemplates a combination of active ingredients for the treatment of atopic dermatitis. 20 I. Definitions and abbreviations Except where the context clea~ly indicates otherwise, the single form as used herein .. ,. . includes the plural object. When the term "active agent" is used, it can apply to both a single active agent and a mixture of two or more separate active agents. The specific dosage forms, carriers, and the like that are described below are only examples and are not 25 intended to.be all-inclusive of the teachings of the present invention. Abbreviations as used herein generally have their ordinary meanings within the chemical and biological fields. II. Introduction 2 Topical pharmaceutical formulations are the focus of the current invention. Inflammatory conditions may benefit from the use of these rnl!dications. The formulation includes an active ingredient in one aspect. In another viewpoint, the detailing contains no dynamic specialist. Psoriasis and atopic d¢tmatitis can be treated or prevented with the help of these s agents. lla. Topical pharmaceutical preparations The present invention provides, in a first aspect, a) an active agent or its pharmaceutically acceptable salt, hydrate, or solvate; b) solvent ran~;ing from about 5% (w/w) to 15% (w/w); c) and a base. The topical pharmaceutical formulation may also contain up to 0.5% (w/w) 10 water in an exemplary embodiment. In a praiseworthy epitome, the effective drug definition further contains up to around 0.1% (w/w) water. The topical pharmaceutical formulation may also contain up to 0.01 percent (w/w) water in an exemplary embodiment. In a commendable exemplificatiph. all elements of the drug plan are chemically satisfactory. II. a. i. Activator 15 An active pharmaceutical ingredient (also known as an "active agent") is included in an exemplary embodiment of the topical pharmaceutical formulation. An anti-inflammatory agent serves as an example of the active agent. An anti-pruritic agent serves as an example of the actiVe agent. The active agent treats atopic dermatitis in one example. The active ingredient treats psoriasis in one example. A compound· described in this document serves 20 as the active agent in some examples. Benzoxaborol is an example of the active ingredient. The active agents described here, their salts, hydr;ll:cs, or solvates, as well as combinations thereof, are provided by the pr~sent invention in one exemplary embodiment. A model epitome is a blend of chrysabolol and a second dynamic specialist as one dynamic specialist for the treatment of atopic dermatitis or psoriasis. A co-formulation or a mixture of two 25 active ingredients could make up the combination. On the other hand, the mix can be bundled in a gadget with one dynamic specialist in one chamber and one more dynamic fixing in the subsequent chamber, however after iule. The following factors influence the active ingredient is absorbed through the skin: Thin skin ~bsorbs more than thick skin; skin thickness varies depending on the body part, 5 age, and skin condition. The skin's barrier function may be disrupted by dermatitis, ichthyosis, and keratolytic agents like salicylic acid; as a result, it may absorb more rll(-~dication than healthy skin. The retention of the dynamic fi~ing is more noteworthy where there is impediment, for ' example, in the skin folds, under dressings, or when an oily, salve plan is utilized 10 Small molecules are more easily absorbed through the skin than large molecules Lipophilic compounds are better absorbed than hydrophilic compounds Higher concentrations of the active ingredient may penetrate more than lower concentrations Other ingredients in the formulation may inlerOlct to increase or reduce potency or 15 absorption rates. A topical medication's effectiv~.~ess may .be urH!Xpectedly affected by small formulation variations. Quantity of topical formulation~ The most experienced dermatologist may have difficulty deciding how much topical 20 medication to prescribe. Depending on: The vehicle The thickness of the applica.tion The total area to be treated The frequency of the application.~ 10 i The duration of the treatment course. One gram of cream will cover a 10-cm2 area of skin; The ointment goes a little bit further. The amount of cream or ointment required to treat a specific area for a specific amount of time is indicated by the fingertip unit (0.5 g). Two flat hands are covered by one fingertip 5 unit, and the patient's hands are covered by one gram. To cover an adult's entire body once, it takes between 20 and 30 grams of cream or ointment. Vehicles used for topical formulations Topical formulations contain an)ctive ingr'edienr, often a medication or drug or botanical, 10 and a vehicle. The vehicle usually contains water, oil, alcohol or propylene glycol mixed with preservatives, emulsifiers, absorption promoters and fragrances. 15 20' II We claim: 1. Topically material drug readiness including a functioning drug fixing along with at least one drug transporters as well as excipients reasonable for skin organization, where the dynamic drug fixing is a compound chosen from the gathering comprising of roflumilast, salts of roflumilast, the N-oxide of the pyridine build liP of roflumilast or salts thereof. 2. The semisolid dosage form of the topical pharmaceutical preparation described in claim 1 is one of ointments (such as solution ointment or suspension ointment), creams, gels, or pastes. 3. Transdermal therapeutic system (TTS) as defined in claim 1; a topical pharmaceutical preparation. 4. Utilization of roflumilast, its salts, the N-oxide, and roflumilast for the production of a topical pharmaceutical preparation for dermal administration for the systemic treatment of diseases that are thought to be treatable or preventable with the use of POE 4 inhibitors. 5. Utilization of roflumilast, its salts, the N-oxide, and roflumilast for the production of a topical pharmaceutical preparation for dermal administration for the treatment of skin conditions that are thought to be treatable or preventable with the use of POE 4 inhibitors. 6. Topical pharmaceutical formulation containing; Contacting the cells with the topical pharmaceutical formulation of claim 1 is an in vitro method of reducing the release of cytokines, chemokines, or both.